General
publicado em 11/11/2011 às 08h26:00
   Dê o seu voto:

Epigenetic Therapy Shows Promise in Patients with Hard-to-treat Lung Cancer

Patients who received drug combination survived 6.4 months compared with 4 months of untreated patients

 
font size
A-
A+
Foto: Johns Hopkins University
Stephen A. Baylin, pesquisador envolvido no estudo
  « Previous
next »  
Stephen A. Baylin, pesquisador envolvido no estudo

Patients with recurrent metastatic non-small cell lung cancer have a morbid prognosis, but a new epigenetic therapy may have potential for this population, according to data published in Cancer Discovery, a journal of the American Association for Cancer Research.

A research team at Johns Hopkins University tested a combination epigenetic therapy of azacitidine and entinostat among 45 patients with recurrent metastatic non-small cell lung cancer who had been heavily pretreated with other therapies but showed no response. Each patient received azacitidine on nine days and entinostat on two days per month. The trial had an " open-label" design, in which all patients received the treatment and there was no control group receiving a placebo.

Researchers found a median survival of 6.4 months with treatment, where the typical survival for this patient population is four months. Patients who showed signs of gene methylation reversal in at least two of four key genes had better survival than the rest, and two patients experienced dramatic tumor shrinkages.

Four of the 19 patients who received subsequent anticancer therapies had a major objective response to immediate subsequent treatment with other agents. Seven patients remain alive, including two who began treatment approximately four years ago.

" We are starting to show traction for epigenetic therapy for one of the most difficult-to-treat tumors," said Stephen A. Baylin, M.D., professor and deputy director of the Kimmel Cancer Center at Johns Hopkins University and leader of the Stand Up To Cancer (SU2C) Epigenetics Dream Team. " This study appears to show the first durable successes in solid tumors with epigenetic therapy."

This drug combination has previously shown efficacy among patients with leukemia.

" We hope these results lead to a larger, more definitive clinical trial of this drug combination," said Charles Rudin, M.D., Ph.D., professor of oncology and director of the Upper Aerodigestive Cancer Program at Hopkins' Kimmel Cancer Center. Rudin led the team of physicians and cancer biologists who conducted the study.

Source:
  • Share this pageShare this page
  • Share this pageCorrect
  • ShareShare
  • AlertAlert
Reduced link: 
  • You are recommending this story: Epigenetic Therapy Shows Promise in Patients with Hard-to-treat Lung Cancer
  • Fill in the following form to send your recommendation to your friend:

  • You are suggesting a correction for this story: Epigenetic Therapy Shows Promise in Patients with Hard-to-treat Lung Cancer


Receba notícias do iSaúde no seu e-mail de acordo com os assuntos de seu interesse.
Seu nome:
Seu email:
Desejo receber um alerta com estes assuntos:
Epigenetic therapy    lung cancer    the American Association for Cancer Research    Johns Hopkins University    Stephen A. Baylin   
Comments:
Comment
Leave your comment
Close
(Required fields are marked with an *)

(Your email address will never be published or shared.)

Enter the letters and numbers below and click in the button "send"

  • Twitter iSaúde
advertising
Informe Saúde printed version

Recommend the portal
Close [X]
  • You are recommending this story: http://www.isaude.net
  • Fill in the following form to send your recommendation to your friend:

RSS news from the portal  iSaúde.net
Get the newsletter of the portal  iSaúde.net
Recommend the portal iSaúde.net
News from  iSaúde.net in your blog or website.
Get news on the subject of your interest.
© 2000-2011 www.isaude.net Todos os direitos reservados.